GeoVax Labs, Inc. senior leadership will participate in key European meetings over the coming weeks to advance partnering discussions for the company's vaccine and immunotherapy portfolio. Chairman and CEO David A. Dodd and Vice President John Sharkey, PhD, will lead the company's presence at World Vaccine Congress Europe in Amsterdam from October 14-16 and BIO-Europe Fall in Vienna from November 3-5.
The European engagements represent a strategic effort to accelerate development of critical medical countermeasures. Beyond conference activities, the GeoVax team will conduct meetings with global non-governmental organizations including WHO, UNICEF, CEPI, Gavi, and the Africa CDC, as well as established and prospective academic institutional collaborators across Europe. These discussions aim to address significant public health challenges through collaborative development and manufacturing partnerships.
David A. Dodd emphasized the importance of these engagements, stating the company is focused on solidifying durable relationships that can accelerate development in support of expanded access to critical vaccines and immunotherapies. The partnering priorities include near-term opportunities in mpox and smallpox preparedness, addressing unmet needs of immunocompromised patients relative to COVID-19, expanding development of Gedeptin® as neoadjuvant cancer therapy, and exploring complementary collaborations across the company's broader platform.
GeoVax will highlight several key programs during the European meetings. The GEO-MVA mpox and smallpox vaccine candidate represents a U.S.-based MVA program designed to accelerate access to a second-source of critically needed vaccine with rapid, scalable manufacturing capabilities. The GEO-CM04S1 multi-antigen COVID-19 vaccine, designed to elicit robust T-cell and antibody responses, focuses on addressing current unmet needs of an estimated over 400 million immunocompromised patients worldwide. Gedeptin®, a tumor-targeted immuno-oncology approach, shows potential combination synergies with checkpoint inhibitors and could provide new neoadjuvant therapy against solid tumors.
Dr. John Sharkey noted that the company continues to receive compelling interest from governments, NGOs, and potential industry collaborators seeking diversified, resilient vaccine supply and clinically differentiated immunotherapies. The goal is to convert this interest into structured collaborations that accelerate development, manufacturing readiness, and regional availability. Additional information about GeoVax and its programs is available at https://www.geovax.com.
The European partnership initiative comes at a critical time for global health security. The ongoing threat of mpox outbreaks, the persistent vulnerability of immunocompromised populations to COVID-19, and the need for innovative cancer therapies represent significant healthcare challenges worldwide. Successful partnerships could accelerate the availability of these medical countermeasures, potentially benefiting millions of patients and strengthening global health infrastructure against future infectious disease threats and cancer treatment limitations.
